Intraductal Meibomian Gland Probing Trial

Launched by JOSEPH B. CIOLINO, MD · Oct 3, 2014

Keywords

ClinConnect Summary

Dry eye disease is one of the most common conditions seen in ophthalmic practice and is associated with significant patient distress. Meibomian gland dysfunction (MGD) is among the most prevalent causes of dry eye disease. This condition, which is often due to obstruction of the meibomian gland orifices, may result in significant ocular irritation. Traditionally, management of MGD includes warm compress, lid hygiene, and anti-inflammatory medications. This randomized clinical trial is designed to evaluate the effects of meibomian gland probing versus sham procedure in cases with refractory ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18-89 years
• • Willing and able to provide written informed consent
• • Willing and able to comply with study assessments for the full duration of the study
• • Diagnosis of meibomian gland dysfunction (MGD)
• • Symptoms of MGD such as foreign body sensation, burning, stinging, light sensitivity for at least 3 months
• • Persistent symptoms despite at least 3 months of medical management including lid hygiene, warm compress, and use of topical and systemic therapy, or contraindication to systemic therapy
• • Presence of lid tenderness on the upper lids in both eyes
• • Tear break-up time (TBUT) of \<10 seconds
• • In good stable overall health
• Exclusion Criteria:
• • Active allergies to steroids, sulfacetamide, GenTeal PM Night-Time ointment, or lidocaine
• • Intraocular surgery or ocular laser surgery within 1 month before enrollment
• • History of ocular infection within 1 month before enrollment.
• • History of increased intraocular pressure after using topical steroids (steroid responsive)
• • Any condition (including language barrier) that precludes subject's ability to comply with study requirements including completion of study